What is miR Scientific?

miR Scientific, LLC  is a healthcare company committed to transforming global cancer management by providing early and accurate detection, characterization and monitoring of disease using non-invasive liquid biopsy technology.

Our goal is to inclusively partner with all healthcare stakeholders to help change the standards of care and cancer management. 

miR Scientific is developing products and services which may revolutionize the standards of care supporting urologic oncology, including prostate, bladder and kidney cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally.
miR Scientific proudly presents our initial product: the miR Sentinel Prostate Cancer Test, a non-invasive liquid biopsy urine test that detects, classifies and can monitor prostate cancer at the molecular level. miR Scientific is a majority-owned operating subsidiary of Huminn LLC (formerly known as Impact NRS) and is headquartered in New York City with operating subsidiaries in Israel. 

What is the miR Sentinel Prostate Cancer Test? 

The miR Sentinel Prostate Cancer Test is a liquid biopsy urine test that uses molecular information to categorize patients into one of four groups: No Molecular Evidence of Prostate Cancer, Low-Risk, Moderate Risk, or Elevated Risk for Aggressive Prostate Cancer, thereby delivering clear, accurate and actionable results for providers and their patients alike, answering key questions: Is there molecular evidence of prostate cancer? If so, how severe is the risk of aggressive disease? 
With comprehensive molecular insight into prostate cancer, a single test both detects the presence or absence of prostate cancer and classifies it by risk profile, giving miR Sentinel the power to outperform an array of prostate cancer diagnostic procedures.

With data showing a sensitivity above 90% for all prostate cancer as well as GG≥2 prostate cancer, and subset data showing that many patients with false negative prostate biopsies are identified as having molecular evidence of prostate cancer and aggressive prostate cancer shows that there is a clear rationale for adoption of the miR Sentinel Prostate Test versus today's standard of care

When will it be available?

We anticipate that the miR Sentinel Prostate Test will be available in Puerto Rico and the United States (other than New York) by the end of 2021. The Test can only be ordered by your doctor, who will use the test as part of your care and treatment plan.   
Once the miR Sentinel Prostate Test is commercially available, we will update our website with information about costs, any patient assistance programs, and additional helpful details to share with your doctor when discussing your prostate cancer detection and treatment options. 
You may also subscribe to receive our communications via the Contact Us page on our website to receive notifications regarding news and updates of the miR Sentinel Prostate Cancer Test.  

Can I get access through a clinical study?

Several clinical studies are now actively recruiting. Please visit the links provided below to the trial description on clinicaltrials.gov to review study information and eligibility.  

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform now recruiting patients at:  

United States, Georgia 
Georgia Urology 
Atlanta, Georgia, United States, 30328 
Contact: Daniel Canter, MD    404-292-3727       
Urology of Greater Atlanta 
Stockbridge, Georgia, United States, 30281 
Contact: James M Libby, MD    770-474-5281       
United States, New York 
Integrated Medical Professionals 
Farmingdale, New York, United States, 11735 
Contact: Carl A Olsson, MD    516-456-9731      

Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico now recruiting patients at: 
Puerto Rico 
Caguas, Puerto Rico, 00725 
Contact: Alvin Lopez-Pujals, MD    787-743-3038 ext 3235       

Hospital Menonita de Caguas  
Caguas, Puerto Rico, 00726 
Contact: Alberto Corica, MD          
Contact: Federico Corica, MD          
Hospital Metropolitano Dr. Pila  
Ponce, Puerto Rico, 00717 
Contact: Alberto Corica, MD          
Contact: Federico Corica, MD

When It Comes To Cancer, Do You Want More Questions Or More Answers?

Avoid the inaccurate blood tests and painful biopsies and get complete cancer diagnosis and classification information from one urine sample.

Contact miR